DPTX 3496
Alternative Names: DPTX-3496Latest Information Update: 05 Mar 2025
At a glance
- Originator Dewpoint Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Beta catenin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Non-small cell lung cancer; Triple negative breast cancer